

DAY 1	
Rakesh K Jain Harvard Medical School and Massachusetts General Hospital, Boston	Improving Immunotherapy of Glioblastoma by Reprogramming the Tumor Microenvironment: Emerging Insights and Strategies
Tyler Jacks, MIT, Boston	Title to added
Ellen Pure, University of Pennsylvania, PA	Strategies to overcoming multiple challenges to CAR T cell therapy for the treatment of desmoplastic tumors
A Thomas Look, Dana-Farber Cancer Institute, Harvard Medical School, MA	Epigenetic control of neuroblastoma proliferation and cell surface GD2 expression by combining retinoic acid with inhibitors of KAT6A/B enzymatic activity
Douglas Green, St Jude Children's Research Hospital, TN	Paradigm Shifts in Cell Death Research
Kai Wucherpennig, Dana-Farber Cancer Institute, Harvard Medical School, MA	Therapeutic Targeting of the Cancer – Immunity Cycle
John Quackenbush, Harvard T.H. Chan School of Public Health, MA	Network Transitions as Drivers of Disease
Khalid Shah Harvard Medical School, MA	The Concept of Innovation and Orchestration: Translating Cell Based Immunotherapies from Bench to Bedside
Ying-Chih Chang AcroCyte Therapeutics Inc., Taiwan	Cultivating the Future: 3D Cell Cultures and the Path to Personalized Medicine
Channing J Der, UNC School of Medicine, NC	Targeting KRAS for cancer treatment
Oliver Bogler Coaching and Consulting, VT	Special Talk On NIH Funding and Opportunities

DAY 2

Cancer Immunology and Immunotherapy

Geetha Upadhayay, Uniformed Services University, MD

Lucas Ferrari de Andrade, Icahn School of Medicine at Mount Sinai, NY

Xingxing Zhang Albert Einstein College of Medicine, NY	New immune pathways: from fundamental discoveries to novel drugs to new clinical trials
Geetha Upadhayay, Uniformed Services University, MD	Emerging biomarkers for solid cancer-immunotherapies
Megan L. Burger, Knight Cancer Institute, OR	Therapeutic vaccination to remodel antigen hierarchies
Lucas Ferrari de Andrade, Icahn School of Medicine at Mount Sinai, NY	Selective inhibition of Fc receptor shedding to promote antibody-dependent cellular cytotoxicity against tumors
Yufei Wang, Dana-Farber Cancer Institute, MA	Engineering the Next Generation of CAR T Cells for Solid Tumors
Alexander Barrow, Doherty Institute, Australia	NK Cell Receptor Signaling in Cancer Immunotherapy: Mechanistic Insights and Therapeutic Potential
Yina H Huang, Geisel School of Medicine, NH	Contrasting CAR T and nanoparticle delivery of cytokine immunotherapies.
Allison Fitzgerald Dana Farber Cancer Institute, MA	NK Cell Receptor Signaling in Cancer Immunotherapy: Mechanistic Insights and Therapeutic Potential
John Bridgeman, CSO, Immunokey Ltd, UK	CARKey™ - A multi-specific CAR T-cell platform to overcome solid tumour antigen heterogeneity.
Tay Rong En, Singapore Immunology Network, Singapore	Serotonin receptor 5-HT _{2A} as a potential target for HCC immunotherapy.

Cancer Biology, Targeted Therapies & Tumor Microenvironment

Stefanie Galban, University of Michigan, MI

Khosrow Kashfi, CUNY, NY

Anthony Faber, VCU Massey Comprehensive Cancer Center, VA	Title to be updated
Priya Hays, Hays Documentation Specialists, LLC	Advances and Challenges in MRD Measurement for Determining Prognosis by Liquid Biopsy
Stefanie Galban, University of Michigan, MI	Title to be updated
Asaf Rotem, Astrazeneca, MA	Multimodality of Single Cell Analysis in Clinical Settings

Frank Cichocki, University of Minnesota, MN	An intrinsic functional switch governing natural killer cell fate and function in cancer.
J. Javier Bravo-Cordero Icahn School of Medicine at Mount Sinai, NY	The textures of the tumor microenvironment: An integrated imaging perspective
Yu (Clay) Cao, GenEditBio Limited, MA	The development of novel in vivo T cell engineering systems
Rizwan Haq Dana-Farber Cancer Institute, MA	New models of metastatic uveal melanoma to uncover therapeutic targets
Mark Leick, Mass General Brigham Cancer Institute, MA	Title to be updated
Nilay Sethi Dana Farber Cancer Institute, MA	Title to be updated

DAY 3	
Metastasis and Tumor Progression	
William Gmeiner, Wake Forest University School of Medicine, NC Kaifu Chen, Harvard Medical School, MA	
Fatima G. Wilder Brigham and Women's Hospital, Boston, MA	Title to be added
Blake R. Wilde Roswell Park Comprehensive Cancer Center, NY	Metabolic determinants of kidney cancer initiation
Jutatip Panaampon Dana-Farber Cancer Institute, Boston	Title to be added
Francois-Xavier Danlos, Gustave Roussy, France	Building an early-phase cellular therapy program for solid tumors: experience from Gustave Roussy
Rizwan Romee, Dana Farber Cancer Institute, Boston, MA, USA	New models of metastatic uveal melanoma to uncover therapeutic targets
Hyungshin Yim, Hanyang University, South Korea	PLK1 signaling network as a driver of metastasis in NSCLC
Angus Gordon Imperial College Healthcare Trust, London	Tumour Volume Analysis applied to Breast cancer
Minji Jung, Stanford University, CA	Bidirectional Links Between Kidney Cancer and Cardiovascular Disease: Emerging Epidemiologic Insights

Drug Discovery and Preclinical Models Lee Graves, University of North Carolina, NC Eric Humke, EpiBiologics, CA	
Khosrow Kashfi, CUNY, NY	Title to be added
Eric Humke, CMO, EpiBiologics, CA	Title to be added
Lee Graves, University of North Carolina, NC	Title to be added
Richard Kolesnick Memorial Sloan Kettering Cancer Center, NY	Title to be updated
Hernando Lopez Bertoni, Johns Hopkins School of Medicine, Baltimore	Resistance Is Futile: Collapsing Networks to Outmaneuver GBM
Yunqing Li Hugo W. Moser Research Institute at Kennedy Krieger, MD	Targeting tumor cell intrinsic epigenetic determinants in Brain tumors
Leif W. Ellisen MGH Cancer Center, Harvard Medical School, MA	Targeting metabolic reprogramming underlying therapy resistance in TNBC
Mutlay Sayan, Harvard Medical School, MA	Defining the Role of Whole-Pelvis Radiotherapy in Modern Prostate Cancer Care.